PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSulfamethoxazole
Sulfamethoxazole
Bactrim, Gantanol, Septra, Sulfamethoxazole / Trimethoprim, Sulfatrim, Urobak (sulfamethoxazole) is a small molecule pharmaceutical. Sulfamethoxazole was first approved as Gantanol on 1982-01-01. It is used to treat bacterial infections, chlamydiaceae infections, chronic bronchitis, enterobacteriaceae infections, and mycoses amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Bactrim, Septra, Sulfamethoxazole trimethoprim, Sulfatrim (discontinued: Azo gantanol, Bactrim, Cotrim, Cotrim d.s, Septra, Septra grape, Sulfamethoxazole trimethoprim, Sulfamethoxazole trimethoprim phenazopyridine, Sulfatrim, Sulfatrim-ss, Trimeth/sulfa, Uroplus, Uroplus ss)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfamethoxazole
+
Trimethoprim
Tradename
Company
Number
Date
Products
SEPTRAMonarch PharmaceuticalsN-017376 RX1982-01-01
1 products
SEPTRA DSMonarch PharmaceuticalsN-017376 RX1982-01-01
1 products
SULFATRIM PEDIATRICPAI PharmaN-018615 RX1983-01-07
1 products
BACTRIMSun Pharmaceutical IndustriesN-017377 RX1982-01-01
1 products, RLD
BACTRIM DSSun Pharmaceutical IndustriesN-017377 RX1982-01-01
1 products, RLD, RS
Show 14 discontinued
Phenazopyridine hydrochloride
+
Sulfamethoxazole
Tradename
Company
Number
Date
Products
AZO GANTANOLRocheN-013294 DISCN1987-09-10
1 products, RLD
Hide discontinued
Sulfamethoxazole
Tradename
Company
Number
Date
Products
GANTANOLRocheN-012715 DISCN1982-01-01
1 products
GANTANOL-DSRocheN-012715 DISCN1982-01-01
1 products
GANTANOLRocheN-013664 DISCN1982-01-01
1 products
Hide discontinued
Phenazopyridine hydrochloride
+
Sulfamethoxazole
+
Trimethoprim
Tradename
Company
Number
Date
Products
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDEAble LaboratoriesN-021105 DISCN2001-06-26
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bactrim bactrim dsNew Drug Application2024-12-30
bactrim dsNew Drug Application2024-07-25
sulfamethox-tmp dsANDA2022-10-09
sulfamethoxazole and trimethoprimANDA2025-03-26
sulfamethoxazole and trimethoprim dsANDA2010-04-28
sulfamethoxazole, and trimethoprimANDA2009-10-09
sulfatrimNew Drug Application2025-03-06
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01E: Sulfonamides and trimethoprim antibacterials for systemic use
J01EC: Intermediate-acting sulfonamides
J01EC01: Sulfamethoxazole
J01EE: Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01: Sulfamethoxazole and trimethoprim
J04: Antimycobacterials
J04A: Drugs for treatment of tuberculosis
J04AM: Combinations of drugs for treatment of tuberculosis
J04AM08: Isoniazid, sulfamethoxazole, trimethoprim and pyridoxine
HCPCS
Code
Description
S0039
Injection, sulfamethoxazole and trimethoprim, 10 ml
Clinical
Clinical Trials
247 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_000054431617192071
Communicable diseasesD0031412712131548
Hiv infectionsD015658EFO_0000764B20481851143
PneumoniaD011014EFO_0003106J1827195939
Pneumocystis pneumoniaD011020EFO_0007448B5937145834
Urinary tract infectionsD014552EFO_0003103N39.017591132
MalariaD008288EFO_0001068B54191314
Acquired immunodeficiency syndromeD000163EFO_0000765B20133310
AbscessD000038EFO_000303022610
BacteremiaD016470EFO_0003033R78.813137
Show 65 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Staphylococcal infectionsD013203A49.0155615
Bacterial infectionsD001424A4931127
SepsisD018805EFO_0001420A41.91337
Multiple myelomaD009101C90.01415
Plasma cell neoplasmsD0542191415
SyndromeD01357722115
NeoplasmsD009369C803214
FibrosisD005355224
Kidney diseasesD007674EFO_0003086N0822114
Lung diseasesD008171EFO_0003818J98.4122
Show 38 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prosthesis-related infectionsD016459EFO_1001406123
Healthy volunteers/patients22
Congenital microtiaD065817Q16.011
Brain neoplasmsD001932EFO_0003833C7111
GlioblastomaD005909EFO_000051511
AstrocytomaD001254EFO_000027111
Macular degenerationD008268EFO_0001365H35.3011
Geographic atrophyD05709211
AtrophyD00128411
Small cell carcinomaD01828811
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BronchitisD001991J4033
HypospadiasD007021EFO_0004209Q5433
UlcerD014456MPATH_57922
Surgical wound infectionD01353022
Retinal detachmentD012163EFO_0005773H33.211
Aortic dissectionD000784I71.011
Long qt syndromeD008133HP_0001657I45.8111
DeliriumD003693R41.011
Torsades de pointesD016171EFO_0005307I47.2111
Whooping coughD014917EFO_0000650A3711
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSulfamethoxazole
INNsulfamethoxazole
Description
Sulfamethoxazole is an isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position. It has a role as an antibacterial agent, an antiinfective agent, an epitope, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an antimicrobial agent, a P450 inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, an environmental contaminant, a xenobiotic and a drug allergen. It is a sulfonamide, a member of isoxazoles, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide.
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Identifiers
PDB
CAS-ID723-46-6
RxCUI
ChEMBL IDCHEMBL443
ChEBI ID9332
PubChem CID5329
DrugBankDB01015
UNII IDJE42381TNV (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Sulfamethoxazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Sulfamethoxazole
+
Trimethoprim
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 59,001 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
42,513 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use